Sionna Therapeutics (NASDAQ:SION) Coverage Initiated by Analysts at Citizens Jmp

Citizens Jmp began coverage on shares of Sionna Therapeutics (NASDAQ:SION) in a report published on Tuesday, MarketBeat.com reports. The brokerage issued a market outperform rating and a $63.00 target price on the stock.

A number of other equities analysts have also commented on SION. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sionna Therapeutics in a research note on Monday, December 29th. Lifesci Capital initiated coverage on Sionna Therapeutics in a research report on Tuesday, December 23rd. They issued an “outperform” rating and a $60.00 target price for the company. Royal Bank Of Canada reiterated an “underperform” rating and set a $24.00 price target on shares of Sionna Therapeutics in a report on Monday, December 1st. Wall Street Zen raised Sionna Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. Finally, BTIG Research restated a “buy” rating and set a $58.00 price objective on shares of Sionna Therapeutics in a research report on Wednesday, January 14th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Sionna Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $47.63.

Sionna Therapeutics Trading Up 3.4%

SION stock opened at $37.32 on Tuesday. Sionna Therapeutics has a one year low of $7.26 and a one year high of $45.00. The firm has a 50-day moving average of $40.12 and a two-hundred day moving average of $34.77. The firm has a market capitalization of $1.67 billion and a PE ratio of -7.66.

Insiders Place Their Bets

In related news, major shareholder Tpg Gp A, Llc sold 250,000 shares of the business’s stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $40.00, for a total value of $10,000,000.00. Following the completion of the sale, the insider owned 6,494,962 shares of the company’s stock, valued at approximately $259,798,480. The trade was a 3.71% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Peter A. Thompson sold 33,356 shares of the stock in a transaction that occurred on Wednesday, December 24th. The stock was sold at an average price of $44.55, for a total value of $1,486,009.80. Following the completion of the transaction, the director owned 3,561,655 shares in the company, valued at $158,671,730.25. This represents a 0.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 382,368 shares of company stock valued at $15,898,607 in the last three months. Insiders own 3.90% of the company’s stock.

Institutional Trading of Sionna Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Braidwell LP acquired a new position in shares of Sionna Therapeutics during the 2nd quarter worth $18,770,000. Eventide Asset Management LLC bought a new stake in Sionna Therapeutics in the fourth quarter worth $26,290,000. Vanguard Group Inc. increased its position in Sionna Therapeutics by 81.4% during the third quarter. Vanguard Group Inc. now owns 1,143,154 shares of the company’s stock worth $33,620,000 after buying an additional 512,803 shares during the last quarter. State Street Corp increased its position in Sionna Therapeutics by 188.7% during the fourth quarter. State Street Corp now owns 693,395 shares of the company’s stock worth $28,526,000 after buying an additional 453,196 shares during the last quarter. Finally, Viking Global Investors LP raised its holdings in Sionna Therapeutics by 8.2% during the second quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock valued at $55,436,000 after buying an additional 242,427 shares in the last quarter.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.